# Invasive laser acupuncture vs. electroacupuncture for non-specific chronic low back pain: protocol for a randomized clinical trial

**Authors:** Yejin Hong, Dongwoo Nam, Changsop Yang, Byoung-Kab Kang, Ae-Ran Kim, Kyung Min Shin, Jihye Kim, Saerom Jeon, Gwang-Cheon Park, Jeong-Cheol Shin, Jae-Hong Kim

PMC · DOI: 10.3389/fmed.2025.1659696 · Frontiers in Medicine · 2025-10-30

## TL;DR

This study compares laser acupuncture and electroacupuncture for chronic back pain, aiming to determine which is more effective in reducing pain.

## Contribution

The study introduces a novel comparison of 650 nm invasive laser acupuncture versus electroacupuncture for non-specific chronic low back pain.

## Key findings

- The trial will assess the short-term efficacy of ILA and EA using the Visual Analog Scale.
- Safety and adverse events will be monitored to evaluate treatment risks.
- Results will provide evidence on the comparative effectiveness and safety of these acupuncture methods.

## Abstract

This study aims to evaluate the short-term efficacy of 650 nm invasive laser acupuncture (ILA) compared to conventional electroacupuncture (EA) in reducing pain in patients with non-specific chronic low back pain (NSCLBP).

This is a prospective, multicenter, randomized, single-blind, controlled trial. Ninety patients with NSCLBP will be recruited and randomly assigned (1:1) to receive either 650 nm ILA or EA. Treatments will be administered at the bilateral acupoints BL23, BL24, BL25, and GB30 for 10 min per session, twice weekly for 4 weeks (8 sessions in total). The primary outcome is the change in the Visual Analog Scale (VAS) score 1 week after treatment completion. Secondary outcomes include VAS scores at interim and follow-up time points, Oswestry Disability Index, European Quality of Life Five Dimension Five-Level Scale, and the proportion of responders. Safety assessments and adverse event monitoring will be conducted throughout the trial.

This multicenter randomized controlled trial compares the effects of ILA and EA with the change in VAS as a primary efficacy endpoint in 90 patients with NSCLBP. This findings will provide clinical evidence of the comparative efficacy and safety of 650 nm ILA versus EA in patients with NSCLBP, supporting its potential as a viable non-pharmacological treatment option.

https://cris.nih.go.kr/cris/search/detailSearch.do?search_lang=E&focus=reset_12&search_page=M&pageSize=10&page=undefined&seq=29960&status=5&seq_group=29960, identifier KCT0010475.

## Full-text entities

- **Diseases:** NSCLBP (MESH:D017116), pain (MESH:D010146)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12611920/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12611920/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12611920/full.md

---
Source: https://tomesphere.com/paper/PMC12611920